Back to results
US 8,912,203 B2Granted
6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
AssigneeAfraxis Holdings, Inc.
InventorsDavid Campbell, Sergio G. Duron, Benedikt Vollrath, Warren Wade
Life of this patent
Estimating the term…
Abstract
Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders.
Claims32
A compound having the structure of Formula I or a pharmaceutically acceptable salt, solvate, or N-oxide thereof:
- wherein:
- ring T is aryl or heteroaryl;
- R3 is —S(═O)R9, (R)—S(═O)R9, (S)—S(═O)R9, or —S(═O)2R9;
- each R4 is independently halogen, —CN, —NO2, —OH, —OCF3, —OCF2H, —OCFH2, —CF3, —SR8, —S(═O)R9, —S(═O)2R9, —NR10S(═O)2R9, —S(═O)2N(R10)2, —C(═O)R9, —OC(═O)R9, —CO2R10, —N(R10)2, —C(═O)N(R10)2, —NR10C(═O)R10, —NR10C(═O)OR10), —NR10C(═O)N(R10)2, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted heteroalkyl, or substituted or unsubstituted cycloalkyl;
- R8 is H or R9;
- R9 is substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
- each R10 is independently H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or two R10 together with the atoms to which they are attached form a substituted or unsubstituted heterocycle;
- s is 0-4;
- Q is substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted heterocycloalkylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heteroarylalkyl;
- ring B is aryl or heteroaryl;
- each R5 is independently halogen, —CN, —NO2, —OH, —OR10, —SR8, —S(═O)R9, —S(═O)2R9, —NR10S(═O)2R9, —S(═O)2N(R10)2, —C(═O)R9, —OC(═O)R9, —CO2R10, —N(R10)2, —C(═O)N(R10)2, —NR10C(═O)R10, —NR10C(═O)OR10, —NR10C(═O)N(R10)2, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl;
- and
- r is 0-8.
10 more elements
A compound selected from:
- and
- pharmaceutically acceptable salts, solvates, or N-oxides thereof.
Dependencies are inferred from the claim text.